This collection highlights real stories of triple-negative breast cancer patients who achieved long-term survival through multiple lines of treatment—options often not fully detailed in standard guidelines
CASE SELECTION 4: Long-Term Survival with Stage 4 HER2-Positive Breast Cancer Read More »
The FDA has just approved zongertinib (brand name Hernexeos) – a new targeted pill – for adults with advanced non-small cell lung cancer (NSCLC) that carries a specific HER2 gene mutation.
Zongertinib: A New Hope for HER2-Mutant Lung Cancer Read More »
New treatments and smarter strategies are transforming what was once a nearly hopeless scenario into one with genuine hope and possibility. Today, experts urge patients not to be discouraged by outdated averages, because outcomes are improving every year and can vary widely depending on individual factors.
A Decade of Progress: Rising 5-Year Survival in Stage IV Gastric Cancer Read More »
Not long ago, a diagnosis of stage IV colon cancer – cancer that has spread to distant organs – was often seen as a dire situation. Historically, five-year survival rates were in the low double digits, and many patients felt they were facing insurmountable odds. But today, we are witnessing a new era of hope. In the last decade, survival statistics have significantly improved, and more patients are defying the old expectations.
Stage IV Colon Cancer Survival: A Decade of Dramatic Improvement and Hope Read More »
Stage IV lung cancer was once considered almost hopeless, with very few patients surviving five years. But in the last decade, new treatments have significantly improved those odds. Today, more stage IV lung cancer patients are living longer – some well beyond five years – thanks to breakthroughs like targeted therapies and immunotherapy. This article
Advanced Lung Cancer: Dramatic Improvements in 5-Year Survival Offer New Hope Read More »
This collection highlights real stories of triple-negative breast cancer patients who achieved long-term survival through multiple lines of treatment—options often not fully detailed in standard guidelines
CASE SELECTION 3: Long-Term Survival with Advanced Triple-Negative Breast Cancer Read More »
This collection highlights real stories of stage 4 colorectal cancer patients with extensive metastases who achieved long-term survival through multiple lines of treatment—options often not fully detailed in standard guidelines.
CASE SELECTION 2: Long-Term Survival with Extensively Metastatic Colorectal Cancer Read More »
In this first collection, we discuss EGFR-TKI-resistant in stage 4 NSCLC. Despite negative prognosis statistics, many patients have achieved long-term survival by undergoing multiple lines of treatment—an option not always explicitly detailed in standard treatment guidelines (You can download FREE HERE). This underscores the importance of self-advocacy and proactive discussions with your doctor to push for personalized treatment plans.
CASE SELECTION 1: Long-Term Survival with EGFR-TKI-Resistence in Stage 4 NSCLC Read More »
Early Access Programs (EAPs) provide a valuable solution, helping patients access new treatments even before official approval in their home countries. This article discusses these programs globally and outlines proactive steps patients and caregivers can take.
Early Access Program For Non-Approved Medicines Outside the US Read More »
This document summarizes key clinical trial findings for Dato-DXd in non-small cell lung cancer (NSCLC), focusing on results from two studies: the Phase II TROPION-Lung05 and the Phase III TROPION-Lung01 trials. Special attention is given to the outcomes in patients with EGFR-mutated disease, including a deeper analysis of Dato-DXd’s potential role in this molecular subgroup.
UNDERSTANDING DATO-DXd CLINICAL TRIAL RESULTS IN NSCLC Read More »
